Management of OAB in Female Patients .

Elsayed Abdelhalim Elsayed300 enrolled

Overview

The objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (OAB) in a double-blinded prospective randomized placebo-controlled trial.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

300

Conditions

Overactive Bladder

Interventions

SolfenacinDRUG

pills taken once day

MirabegronDRUG

pills taken once day

Tadalafil 5mgDRUG

pills taken once day

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women from 18 to 65 years of age with LUTs due to OAB Exclusion Criteria: * Severe cardiovascular disorders. \\ * Severe neurogenic dysfunction. * Drug administration which interfere with bladder function . * Abnormal bleeding profile. * A verified urinary tract infection as determined by urinalysis and/or urine culture during screening

Locations (1)

Kafrelsheikh University hospital

Kafr ash Shaykh, Egypt

Outcomes

Primary Outcomes

overactive bladder symptoms score (OABSS)

OABSS is a symptom assessment questionnaire designed to quantify OAB symptoms into a single score The questionnaire consists of 4 questions on OAB symptoms with maximum scores ranging from 2 to 5: daytime frequency (2 points), night-time frequency (3 points), urgency (5 points), and UUI (5 points). The total score ranges from 0 to 15 points, with higher scores indicating higher symptom severity.

Time frame: three months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.